Want to see BTCY full AI Analyst Report?
Biotricity (BTCY) AI Stock Analysis
Top Page
Biotricity
(Other OTC:BTCY)
The score is held down primarily by a high-risk financial position (negative equity, meaningful debt, and ongoing net losses) despite an operational turnaround. Technicals also remain weak with the price below key long-term moving averages and a negative MACD. Valuation offers limited support because the company is not profitable (negative P/E) and there is no dividend yield provided.
Biotricity (BTCY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.10M
- Dividend Yield
- ―
- Average Volume (3M)
- 44.43K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 0.01
- Revenue Growth
- 13.40%
- EPS Growth
- 43.26%
- Country
- US
- Employees
- 46
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Biotricity Business Overview & Revenue Model
Company Description
Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States. The company's efforts are dedicated to supplying remote monitoring capa...
Biotricity Earnings Call Summary
The call conveyed clear operational momentum: double-digit revenue growth, meaningful gross margin expansion (+516 bps), consecutive positive EBITDA quarters (3) and six consecutive quarters of positive free cash flow, plus strong digital user and provider network expansion. Remaining challenges include a continued net loss ($1.1M), modest absolute revenue scale ($4.0M quarterly), concentration of revenue in technology fees (91.2%), and dependence on future FDA/regulatory clearances and large-account sales cycles. Overall, the positives (margin improvement, recurring revenue, cash-flow and EBITDA momentum, product traction and distribution reach) outweigh the remaining execution and scale risks.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
In the Q3 FY2026 call (period ended Dec. 31, 2025) management guided to continued top-line growth and a shift to profitability in calendar 2026—expecting to turn net‑income positive this year—citing Q3 revenue of $4.0M (up 10.2% vs. $3.6M), technology fees at 91.2% of revenue, gross profit $3.3M (+17.6% YoY) and gross margin 81.5% (up 516 bps from 76.4%), operating expenses $2.8M (down 4.2% YoY) with SG&A down 8.2% (~$195K) and R&D up $72K, EBITDA of $280K ($0.01/share) marking three consecutive quarters of positive EBITDA and six consecutive quarters of positive free cash flow, a net loss of $1.1M (vs. $1.3M) and loss per share $0.042 (vs. $0.054); they also highlighted user growth from 4,500 to >44,000 in two years, >2,500 providers supporting ~400,000 patients annually, expanded Biocore Pro pilots, GPO access to >90% of U.S. hospitals, and stated additional margin and expense improvements are expected with upcoming FDA clearances and international approvals.
Biotricity Financial Statement Overview
Summary
Operations are improving (strong revenue growth, very high gross margins, and positive operating profit in TTM), but the capital structure is a major drag: negative stockholders’ equity, sizable debt relative to scale, and continued net losses. Cash flow shows only a small and inconsistent improvement, limiting near-term deleveraging capacity.
Income Statement
54NeutralBalance Sheet
18Very NegativeCash Flow
33Negative| Breakdown | TTM | Mar 2026 | Jun 2025 | Mar 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.40M | 16.00M | 13.79M | 12.06M | 9.64M | 7.65M |
| Gross Profit | 13.36M | 12.95M | 10.56M | 8.36M | 5.44M | 4.57M |
| EBITDA | 1.86M | 2.44M | -3.21M | -6.73M | -16.07M | -18.56M |
| Net Income | -2.69M | -2.40M | -8.42M | -14.09M | -18.66M | -29.13M |
Balance Sheet | ||||||
| Total Assets | 6.02M | 6.45M | 5.64M | 5.94M | 6.51M | 16.68M |
| Cash, Cash Equivalents and Short-Term Investments | 466.50K | 149.79K | 365.14K | 786.06K | 570.46K | 12.07M |
| Total Debt | 26.93M | 27.06M | 26.09M | 23.88M | 19.55M | 15.35M |
| Total Liabilities | 39.72M | 39.41M | 35.66M | 35.92M | 26.36M | 18.82M |
| Stockholders Equity | -33.69M | -32.96M | -30.01M | -29.98M | -19.85M | -2.14M |
Cash Flow | ||||||
| Free Cash Flow | 161.66K | -718.96K | -2.38M | -6.69M | -13.55M | -15.19M |
| Operating Cash Flow | 161.66K | -718.96K | -2.38M | -6.69M | -13.55M | -15.16M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | -29.77K |
| Financing Cash Flow | -68.90K | 557.74K | 1.93M | 6.74M | 2.00M | 25.17M |
Biotricity Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTCY, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.08, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 49.15 is Neutral, neither overbought nor oversold. The STOCH value of 105.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BTCY.
Biotricity Risk Analysis
Biotricity disclosed 50 risk factors in its most recent earnings report. Biotricity reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksBiotricity Peers Comparison
Overall Rating
HSCS49Neutral- BTCY42Neutral
VVOS40Underperform
ADGM39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HSCS | 49Neutral | $16.45M | -1.03 | -816.25% | ― | -27.70% | 61.44% |
| BTCY | 42Neutral | $1.20M | -0.42 | 8.23% | ― | 13.40% | 43.26% |
| VVOS | 40Underperform | $3.82M | -0.06 | 2616.82% | ― | 45.21% | -10.29% |
| ADGM | 39Underperform | $2.28M | -0.06 | -661.85% | ― | -100.00% | 70.33% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BTCY | Biotricity | 0.06 | -0.49 | -89.81% | |
| VVOS | Vivos Therapeutics, Inc. | 0.11 | -2.36 | -95.43% | |
| ADGM | Adagio Medical Holdings, Inc | 0.08 | -1.01 | -92.39% | |
| HSCS | Heart Test Laboratories, Inc. | 3.31 | 0.38 | 12.97% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026